Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and Axitinib in Advanced Renal Cell Cancer
NCT02493751Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2015
- Primary completion
- Apr 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of avelumab in renal cell carcinoma (RCC), sponsored by Pfizer. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Oct 2015; status: completed.
02
Drugs
avelumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02493751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02493751.